Instem plc Contract Win with US Government Research Agency
November 07 2012 - 2:00AM
RNS Non-Regulatory
TIDMINS
Instem plc
07 November 2012
07 November 2012
Embargoed for 07:00
Instem plc
("Instem", the "Company" or the "Group")
Contract Win with U.S. Government Research Agency
Provantis Preclinical Software Chosen to Advance Key NIAID
Research Programs
Instem plc (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, announces today that
the National Institute of Allergy and Infectious Diseases (NIAID),
part of the National Institutes of Health (NIH), has selected
Instem's integrated Provantis(R) preclinical software suite to help
advance research programs against infectious, immunologic, and
allergic diseases.
Provantis is being deployed within U.S. based laboratories where
NIAID conducts basic and applied research activities aimed at
improving public health in the United States and around the
world.
Phil Reason, CEO of Instem plc, commented: "It is a great
affirmation of Instem's products that another US Government Agency
has selected our software. The award of this contract is very
exciting for Instem as the NIH invests over $30.9 billion annually
in medical research and Instem has been actively targeting
institutions and projects directly or indirectly funded from this
budget."
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser &
Broker) +44 (0) 20 3205 7500
Aubrey Powell
Joe Stroud
Newgate Threadneedle +44 (0) 20 7653 9850
Caroline Evans-Jones
Fiona Conroy
About Instem plc
Instem is a leading supplier of IT solutions to the early
development healthcare market. Instem's pre-clinical study
management solutions accelerate drug and chemical development by
increasing productivity, automating processes and enhancing
practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China,
India and Japan, including 16 of the top 20 pharmaceutical and
biotech companies such as GlaxoSmithKline and AstraZeneca. The
Group employs over 110 people in seven offices in the US, UK, China
and India; and has a full service distributor in Japan. It is
estimated that approximately half of the world's pre-clinical drug
safety data has been collected over the last 20 years via Instem
software, making Instem an ideal partner to help unlock the
scientific/commercial value from these legacy repositories.
To learn more about Instem please visit the Company's website,
www.instem.com, or its investor centre
http://investors.instem.com/.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMMGMMVFGZZZ
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024